[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"erectile-dysfunctions\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:erectile-dysfunctions":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,47,73,101,127,151],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100638916","phase-2-a-single-arm-dose-escalation-of-an-intraurethral-alprostadil-paste-for-erectile-dysfunction-100638916",false,"NCT07601646","A Single-Arm, Dose Escalation of an Intraurethral Alprostadil Paste for Erectile Dysfunction","Phase 2 Clinical Trial of ST-04 Intraurethral Paste for Erectile Dysfunction","Inclusion Criteria:\n\n* Have had a confirmed clinical diagnosis of ED for more than three months based upon IIEF\n* Have failed PDE5 inhibitor therapy (inability to achieve an erection with adequate rigidity to allow penetrative sex)\n* Ability to take oral medication (sildenafil) and be willing to adhere to the study intervention regimen\n* Engaged in heterosexual relationship with partner for a minimum of 6 months\n\nExclusion Criteria:\n\n* History of unstable medical or psychiatric condition that, in the opinion of the principal investigator, could impact the patient's ability to complete the study investigations or protocol.\n* Spinal cord injury, or penile anatomical abnormalities\n* Cardiovascular conditions that prevent sexual activity (NYHA Class II or higher, any angina, or uncontrolled CHF or severe coronary artery disease)\n* History of myocardial infarction, stroke, or life-threatening arrhythmia within 6 months prior to enrollment into the study\n* Use of anti-androgens, or oral or injectable androgens\n* Documented hypotension or known orthostatic hypotension\n* Use of oral, topical or sublingual nitrates within 3 months prior to enrollment into the study\n* Hepatic (Child-Pugh Class C) or renal failure (eGFR \\\u003C 30)\n* Inadequate response to intracavernosal injection therapy previously\n* Peyronie's disease or Meatal stenosis","MALE","21 Years","75 Years",{"count":20,"type":21},83,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This is a single arm dose escalation trial of a mucoadhesive intraurethral polymer suspension of alprostadil (ST-04) and will investigate the efficacy of 3 dose levels of ST-04 in adult males with a clinical diagnosis of Erectile Dysfunction (ED). This study aims to determine if ST-04, with or without sildenafil, will improve erectile function (EF) compared to baseline.\n\nParticipants in this study will receive ST-04, a new formulation containing the vasodilator, alprostadil which is known to be an effective drug in treating erectile dysfunction. ST-04 will be dispersed along the urethra, forming a hydrogel which adheres to the lining of the urethra with the goal of penile tumescence and erection. Participants may receive up to 3 dose level escalations of ST-04 over a 12-week period, for a total of up to 11 administrations of ST-04. Dose escalation may also be done with and without sildenafil.",[27,28,29],"Erectile Dysfunction (ED)","Erectile Dysfunctions","Erectile Function",[31,29,32,33],"Erectile Dysfunction","Alprostadil","Sildenafil","RECRUITING","2026-05-20",{"date":37,"type":38},"2026-05-22","ACTUAL",{"date":40,"type":21},"2026-05",{"date":42,"type":21},"2027-05",{"name":44,"class":45},"Ryan Flannigan, MD","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":57,"studyType":58,"phases":4,"briefSummary":59,"conditions":60,"keywords":61,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":46},"100630400","a-survey-of-traditional-medicine-pattern-identification-in-patients-with-erectile-dysfunction-100630400","NCT07487181","A Survey of Traditional Medicine Pattern Identification in Patients With Erectile Dysfunction","Traditional Medicine Pattern Distribution in Patients With Erectile Dysfunction: A Cross-sectional Study","Inclusion Criteria:\n\n* Individuals aged 18 years or older who were diagnosed with erectile dysfunction by a clinical physician at Binh Dan Hospital between January 2026 and August 2026.\n* Willing to participate in the study and provide informed consent.\n\nExclusion Criteria:\n\n* Unable to understand the questionnaire.\n* Unable to complete all the study questions.\n* Patients who do not wish to continue participating in the study.","18 Years",{"count":56,"type":21},375,"1 Day","OBSERVATIONAL","Erectile dysfunction (ED) is a common condition that significantly affects quality of life, psychological well-being, and interpersonal relationships. In Traditional Medicine, ED is classified into different syndrome patterns, which are essential for guiding individualized treatment; however, evidence on their distribution and associated factors in Vietnam remains limited. This cross-sectional study aims to determine the distribution of Traditional Medicine syndrome patterns in patients with ED and to evaluate their associations with demographic characteristics, clinical features, psychological status, and lifestyle factors, thereby providing evidence to support improved diagnosis and integrative treatment approaches.",[28],[62,28,63],"Traditional Medicine Pattern","IIEF-5","2026-03-17",{"date":66,"type":38},"2026-03-23",{"date":68,"type":38},"2026-01-14",{"date":70,"type":21},"2026-08-31",{"name":72,"class":45},"University of Medicine and Pharmacy at Ho Chi Minh City",{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":22,"phases":82,"briefSummary":84,"conditions":85,"keywords":86,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":100},"100623049","phase-4-daily-tadalafil-5-mg-combined-with-on-demand-sildenafil-100-mg-for-treatment-of-erectile-dysfunction-in-pde-5i-non-responder-patients-100623049","NCT07391579","Daily Tadalafil 5 mg Combined With On-Demand Sildenafil 100 mg for Treatment of Erectile Dysfunction in PDE-5I Non Responder Patients","Daily Tadalafil 5 mg Combined With On-Demand Sildenafil 100 mg for Treatment of Erectile Dysfunction in PDE-5I Non Responder Patients: A Multicenter Randomized, Double-Blind, Placebo-Controlled Trial","Inclusion Criteria:\n\n* Sexually active male.\n* History of ED for ≥6 months.\n* Erectile function domain of IIEF-15 score \\\u003C17.\n* Documented failure to respond to PDE-5I \\[definition of non-responder patients are patients with ED who don't respond to maximum dose of PDE-5I on ≥4 occasions in spite of accurate timing and good sexual stimulation\\].\n* Stable sexual relationship ≥ 6 months.\n\nExclusion Criteria:\n\n* Penile anatomical deformities or Peyronie's disease.\n* Pelvic surgery or radiation.\n* Active malignancy or severe systemic illness.\n* Previous penile surgery of any kind, such as penile prosthesis, penile lengthening, penile cancer surgery, penile plication or grafting.\n* Contraindication to PDE5i (High risk cardiac patients, patients on nitrates, hypotension).\n* Using other treatments for ED e.g., Intra-cavernoasl prostaglandin injection therapy.",{"count":81,"type":21},500,[83],"PHASE4","The goal of this clinical trial is to evaluate whether daily dosing with tadalafil 5 mg combined with on-demand sildenafil 100 mg can improve erectile function in men with erectile dysfunction (ED) who do not respond to PDE5 inhibitor alone.\n\nThe main questions it aims to answer are:\n\n* Does the combination of daily tadalafil and on-demand sildenafil lead to a greater improvement in erectile function (measured by the IIEF-EF domain) compared with on-demand sildenafil alone?\n* Is the combination therapy safe and well tolerated in this patient population?\n\nResearchers will compare:\n\n* Group A: Daily tadalafil 5 mg plus on-demand sildenafil 100 mg\n* Group B: Daily placebo plus on-demand sildenafil 100 mg\n\nto determine whether the combination regimen provides superior improvement in erectile function and patient satisfaction.\n\nParticipants will:\n\n* Undergo baseline assessment including medical history, physical examination, and laboratory tests.\n* Be randomly assigned to one of the two treatment groups.\n* Take the assigned medications for 12 weeks.\n* Complete follow-up evaluations at 4, 8, and 12 weeks, including:\n\nInternational Index of Erectile Function (IIEF-15) questionnaire Erection Hardness Score (EHS) assessment Reporting of any adverse effects",[28],[31,87,33,88,89,90],"ED","Tadalafil","PDE5i Non-Responders","Combination Therapy","2026-02-02",{"date":93,"type":38},"2026-02-06",{"date":95,"type":38},"2025-12-01",{"date":97,"type":21},"2027-06",{"name":99,"class":45},"Mansoura University",11,{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":108,"enrollmentInfo":109,"targetDuration":4,"studyType":22,"phases":111,"briefSummary":113,"conditions":114,"keywords":4,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":4},"100617863","acupuncture-for-erectile-dysfunction-100617863","NCT07324148","Acupuncture for Erectile Dysfunction","Acupuncture for Erectile Dysfunction Among Patients With Chronic Prostatitis\u002FChronic Pelvic Pain Syndrome: a Clinical Trial","Inclusion Criteria:\n\n* Conforms to the diagnosis of CP\u002FCPPS and pED at the same time;\n* Aged between 18-50 years old;\n* 8≤IIEF-5 score≤21\n* Have a fixed sexual partner and a regular sexual intercourse of ≥1 time\u002Fweek during treatment period;\n* Voluntarily sign an informed consent form.\n\nExclusion Criteria:\n\n* Patients with drug-induced or organic ED.\n* The existence of lesions that may affect erectile function, such as penile cancer, penile sclerosis, penile anatomical deformity, testicular cancer, urinary system stones or neuropathy, etc.\n* History of trauma or surgery in pelvic region.\n* Patients with hypogonadism.\n* Usage of drugs or therapies that relieve CP\u002FCPPS or ED symptoms in the previous 1 month.\n* Have received hormonal or psychiatric drugs in the previous 3 months.\n* Bladder outlet obstruction, overactive bladder, neurogenic bladder, interstitial cystitis, glandular cystitis, sexually transmitted diseases, bladder tumors, prostate cancer, penile cancer, penile stone, other types of prostatitis.\n* With a residual urine ≥100ml.\n* Symptomatic urinary tract infection.\n* Diseases affecting the function of the lower urethra, such as multiple sclerosis, senile dementia, Parkinson's disease, spinal cord injury, caua equina nerve injury, stroke and multisystem atrophy, etc.\n* Severe diseases in heart, lung, brain, liver, kidney and hematopoietic system , mental illness and obvious cognitive function disorders.\n* Patients with poor compliance","50 Years",{"count":110,"type":21},100,[112],"NA","Chronic Prostatitis\u002FChronic Pelvic Pain Syndrome (CP\u002FCPPS) is a prevalent chronic urological disease. CP\u002FCPPS severely impacts patients' quality of life. It is characterized by recurrent pelvic floor pain, lower urinary tract symptoms, and often accompanied by psychological issues and sexual dysfunction (duration ≥3 months, no confirmed infection\u002Fpathology).\n\nThe investigators have completed a large-sample, multi-center randomized controlled trial (RCT) involving 440 patients with CP\u002FCPPS before. The clinical trial confirmed the sustained efficacy of acupuncture for the symptoms of pain, lower urinary tract symptoms, and anxiety and depression among patients with CP\u002FCPPS. However, the trial revealed no significant improvements in sexual dysfunction in the acupuncture group compared to the sham acupuncture group after 8 weeks of treatment.To address this limitation, the current study is designed, which aims to optimize the clinical acupuncture protocol for CP\u002FCPPS and evaluate whether it can enhance outcomes for psychogenic erectile dysfunction (ED) associated. Additionally, mass cytometry and liquid suspension chip technology will be used to explore systemic and local immune mechanisms underlying acupuncture's effects for CP\u002FCPPS. Functional magnetic resonance imaging (fMRI) and metabolomics will be integrated to analyze patients' systemic states from central nervous system and metabolic perspectives, comprehensively elucidating the multi-dimensional mechanisms by which acupuncture alleviates CP\u002FCPPS.",[115,28,116],"Chronic Prostatitis\u002FChronic Pelvic Pain Syndrome (CP\u002FCPPS)","Acupuncture","NOT_YET_RECRUITING","2026-01-06",{"date":120,"type":38},"2026-01-08",{"date":122,"type":21},"2026-01-01",{"date":124,"type":21},"2028-06-30",{"name":126,"class":45},"Guang'anmen Hospital of China Academy of Chinese Medical Sciences",{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":131,"acronym":132,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":18,"enrollmentInfo":134,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":136,"conditions":137,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":46},"100597642","a-potential-relationship-between-treatment-with-tyrosine-kinase-inhibitors-and-erectile-dysfunction-in-male-patients-with-chronic-myeloid-leukemia-100597642","NCT07061145","A Potential Relationship Between Treatment With Tyrosine Kinase Inhibitors and Erectile Dysfunction in Male Patients With Chronic Myeloid Leukemia","ED2024","Inclusion Criteria:\n\n* Patients diagnosed with chronic phase Philadelphia chromosome-positive (Ph+) and\u002For BCR-ABL-positive CML.\n* Patients starting frontline treatment with TKIs between 01st January 2015 and 31st January 2022.\n* Age greater than or equal to 18 years and not exceeding 75 years at the time of starting therapy.\n* Male sex.\n* Exposure to Hydroxyurea or Anagrelide before the initiation of TKI therapy is allowed\n* Ability to provide informed consent, as demonstrated by a clear understanding of the study's objectives and procedures and the ability to make an informed and voluntary decision to participate\n* Signed written informed consent according to ICH\u002FEU\u002FGCP and national and local laws.\n\nExclusion Criteria:\n\n* Patients with advanced phases (accelerated or blastic phase) Ph+ and\u002For BCR-ABL+ CML\n* Patients who experienced ED before TKI initiation",{"count":135,"type":21},350,"Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by the presence of the Philadelphia chromosome, resulting in the constitutive activation of the BCR-ABL1 tyrosine kinase. The advent of tyrosine kinase inhibitors (TKIs) has revolutionized the management of CML, trasforming it from a fatal disease to a chronic condition with excellent long-term outcomes for the majority of patients. The introduction of tyrosine kinase inhibitor (TKI) based treatment for CML has revolutionized the management of this previously fatal disease, achieving sustained disease-control in more than 90% of patients.\n\nHowever, as patients with CML are often required to undergo lifelong TKI therapy to maintain disease control, concerns regarding the long-term safety and tolerability of these agents have emerged.\n\nThe efficacy of second and third-generation TKIs exceeds the efficacy of imatinib, owing to their potent impact on wild-type BCR-ABL1 and various BCR-ABL1 mutants, along with additional drug targets. Furthermore, TKIs exhibit activity on non-kinase targets (es. oxidoreductase NQO2 for nilotinib and imatinib).\n\nThe prolonged treatment duration and expanded TKIs repertoire have led the emergence of various unexpected non-hematologic adverse events (AE), notably vascular adverse events (VAEs).\n\nRecent evidence indicates a relatively high incidence of severe arterial changes in TKI-treated patients, with VAEs frequency correlating with TKI dosage and treatment duration. However, data elucidating the clinical features of vascular events are lacking.\n\nHormonal alterations have been reported in patients treated with imatinib. The tyrosine-kinase receptors cKIT and PDGF receptors, along with their respective ligands, are expressed in the testis, where they play a role in stimulating testosterone secretion by Leydig cells. Prolonged imatinib use has been associated with reduced testosterone production due to PDGFR and cKit blockade in the testis, potentially leading to gynaecomastia in men.\n\nCardiovascular disease (CVD) remains the leading cause of mortality in the United States, accounting for nearly 40% of all deaths. CVD and ED share a variety of common risk factors, including hypertension, diabetes, dyslipidemia, smoking, obesity, physical inactivity, and metabolic syndrome. Screening and diagnosing ED hold significant potential for secondary prevention of CVD. Despite the estabilished association between ED and CVD, the precise mechanisms driving ED's predictive value for CVD are yet to be fully identified. Early deection and treatment of CVD during the critical time frame in which risk factors can be modified will effectively reduce the occurrence of fatal CV events in male patients with ED.\n\nThis is a multicentre national, retrospective, prospective, non-interventional study that focuses on male CML patients starting first-line treatment with TKIs between 1 January 2015 and 31 January 2022.\n\nAll enrolled patients will be involved in both retrospective and prospective evaluations.\n\nThe retrospective component of the study allows the collection of data on the onset of ED, documented in medical records, that occurred before enrolment. It also includes information from physical examinations and laboratory tests, such as complete blood count, serum biochemistry (including renal and liver function tests, lipid profile and glycosylated haemoglobin), molecular biology for BCR-ABL transcript levels and electrocardiography (ECG), collected retrospectively every six months from enrolment until the documented onset of ED. The prospective evaluation assesses the occurrence of ED in the six months prior to enrolment and during the two-year follow-up period.\n\nThe primary objective of the study is to assess the incidence of erectile dysfunction (ED) among male patients with chronic myeloid leukaemia (CML) undergoing treatment with tyrosine kinase inhibitors (TKIs), imatinib, dasatinib, nilotinib, bosutinib or ponatinib, focusing in particular on those individuals who report the appearance of associated symptoms after treatment.",[138,28,139,140],"Chronic Myelocytic Leukemia","CVD - Cardiovascular Disease","Tyrosine Kinase Inhibitor","2025-08-05",{"date":143,"type":38},"2025-08-06",{"date":145,"type":38},"2025-07-01",{"date":147,"type":21},"2028-12",{"name":149,"class":150},"Azienda USL Reggio Emilia - IRCCS","OTHER_GOV",{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":4,"eligibilityCriteria":157,"healthyVolunteers":11,"sex":16,"minAge":158,"maxAge":159,"enrollmentInfo":160,"targetDuration":4,"studyType":22,"phases":162,"briefSummary":164,"conditions":165,"keywords":166,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":4},"100580619","phase-1-umbilical-cord-mesenchymal-stem-cell-secretome-in-severe-erectile-dysfunction-non-responsive-to-sildenafil-100580619","NCT06839651","Umbilical Cord Mesenchymal Stem Cell Secretome in Severe Erectile Dysfunction Non-responsive to Sildenafil","Analysis of the Safety and Efficacy of Administering Umbilical Cord Mesenchymal Stem Cell Secretome in Patients with Severe Erectile Dysfunction Non-responsive to Sildenafil","Inclusion Criteria:\n\n* Men aged 40-65 years who undergo treatment at the Andrology Clinic of RSUD Dr. Soetomo.\n* Severe erectile dysfunction caused by organic factors for at least 6 months, based on an IIEF-5 score of 5-7\n* History of undergoing treatment with sildenafil 100 mg for four sessions.\n* Evaluation of IIEF-5 score \\\u003C 22 and not meeting the MCID criteria, defined as an IIEF-5 score increase of less than 4\n* Type II Diabetes Melitus with an HbA1c test result of \\\u003C 7%.\n* Laboratory test results for liver function (SGOT and SGPT) and kidney function (urea and creatinine) are within normal limits.\n* Patients with undergoing treatment with antidepressant.\n\nExclusion Criteria:\n\n* Anatomical abnormalities of the penis that are clinically visible, such as Peyronie's disease, a history of priapism, a history of penile implants, skin irritation, and lesions in the area surrounding the penile skin.\n* Active and significant systemic or local infection.\n* History of bleeding or blood clotting disorder therapy.\n* History of systemic autoimmune disorders and immunosuppressive treatment\n* History of prostate surgery, history of malignancy, or a PSA level \\> 4 ng\u002FmL.\n* Untreated hypogonadism or low serum total testosterone (\\\u003C200 ng\u002FdL).\n* Uncontrolled hypertension or hypotension (systolic blood pressure \\>170 or \\\u003C90 mmHg, and diastolic blood pressure \\>100 or \\\u003C50 mmHg).\n* Unstable cardiovascular disease (e.g., unstable angina, myocardial infarction within the last 6 months, and congestive heart failure).","40 Years","65 Years",{"count":161,"type":21},10,[163],"PHASE1","The study is an experimental pre-post-test design involving 10 patients with severe ED non-responsive to sildenafil. Safety parameters included pain, hematoma, local bleeding, and infection, while efficacy was measured using the IIEF-5 questionnaire, EHS, and morning erection.",[28],[167,168,169],"Erectile dysfunction","secretome","UC-MSC","2025-02-24",{"date":172,"type":38},"2025-02-25",{"date":174,"type":21},"2025-04-21",{"date":176,"type":21},"2026-04-01",{"name":178,"class":45},"Indonesia University"]